To validate the above findings, we established three different stages of BC progression in a mouse model of TNBC, specifically on days 7, 14, and 21 post-tumor implantation, and assessed the expression levels of the fibroblast marker proteins, α-SMA and CEBPB. The gene discussed is CEBPB; the disease is breast cancer.